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INTRODUCTION 
TUBERCULOSIS 
Tuberculosis (TB) is caused by a bacterium called Mycobacterium 
tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack 
any part of the body such as the kidney, spine, and brain. If not treated 
properly, TB disease can be fatal.
 (1) 
Consumption, phthisis, scrofula, Pott’s disease and the white plague 
are all terms used to refer to tuberculosis throughout history. 
(2) 
  
Spreadability of TB (1)         
TB is spread through the air from one person to another. The TB 
bacteria are put into the air when a person with TB disease of the lungs or 
throat coughs, sneezes, speaks, or sings. People nearby may breathe in these 
bacteria and become infected. TB is NOT spread by  
 Shaking someone's hand 
 Sharing food or drink 
 Touching bed linens or toilet seats 
 Sharing toothbrushes 
 Kissing 
CURRENT STATUS OF TUBERCULOSIS 
TB BURDEN GLOBALLY (20) 
According to WHO global tuberculosis report 
Tuberculosis (TB) is contagious and airborne. It ranks alongside 
HIV/AIDS as a leading cause of death worldwide. 9.6 million People fell ill 
with TB in 2014, including  
1.2 million People living with HIV. In 2014, 1.5 million people died 
from TB, including 0.4 million among people who were HIV-positive.  
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TB is one of the top five killers of women among adult women aged 
20–59 years.  
480 000 women died from TB in 2014, including 140 000 deaths 
among women who were HIV-positive. 890 000 men died from TB and 5.4 
million fell ill with the disease.  
An estimated 1 million children became ill with TB and 140 000 
children died of TB in 2014.  
TB Burden in India
 (20) 
Each year 12 lakh (1,200,000) Indians are notified (that is reported to 
the RNTCP) as having newly diagnosed TB. In addition at least 2.7 lakh 
(270,000) Indians die. Some estimates calculate the deaths as being twice as 
high. TB can affect any age, caste or class but cases are mainly poor people 
and mostly men. Slum dwellers, tribal populations, prisoners and people 
already sick with compromised immune systems are over-represented. 
Globally, a TB associated death happens every 20 seconds. India has 
20 per cent of the global burden of TB. TB is one of the leading causes of 
mortality in India, with nearly 1000 deaths a day.
(21)
  
Latent TB Infection and TB Disease  (1) 
Not everyone infected with TB bacteria becomes sick. As a result, two 
TB-related conditions exist: latent TB infection and TB disease.  
Figure: 1
(3) 
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Latent TB Infection 
TB bacteria can live in the body without making you sick. This is 
called latent TB infection. In most people who breathe in TB bacteria and 
become infected, the body is able to fight the bacteria to stop them from 
growing. People with latent TB infection do not feel sick and do not have any 
symptoms. People with latent TB infection are not infectious and cannot 
spread TB bacteria to others. However, if TB bacteria become active in the 
body and multiply, the person will go from having latent TB infection to 
being sick with TB disease.
(1) 
Figure: 1
(3) 
 
TB Disease 
TB bacteria become active if the immune system can't stop them from 
growing. When TB bacteria are active (multiplying in your body), this is 
called TB disease. People with TB disease are sick. They may also be able to 
spread the bacteria to people they spend time with every day.
 (1) 
Many people who have latent TB infection never develop TB disease. 
Some people develop TB disease soon after becoming infected (within weeks) 
before their immune system can fight the TB bacteria. Other people may get 
sick years later when their immune system becomes weak.  
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For people whose immune systems are weak, especially those with HIV 
infection, the risk of developing TB disease is much higher than for people 
with normal immune system. 
In a country like ours, where the TB bacteria are so prevalent, it is 
imperative to maintain hygiene to prevent the spread of the disease. Spitting 
in public or coughing or sneezing without covering the mouth should be 
completely discouraged.
 (4)
 
Figure: 2 
(5) 
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Some people are known to have a higher risk of progressing from 
latent TB to TB disease. These include: 
 Infants and children aged less than 4 years  
 People infected within the previous two years  
 People infected with HIV 
 People who have certain clinical conditions or conditions which 
compromise their immune system, such as people with diabetes, 
and people with chronic renal failure.  
SYMPTOMS OF TB (6)  
Will generally have no symptoms if are infected with tuberculosis 
(TB), unless have active TB disease. In fact, may not even be aware that you 
have a latent TB infection until it's revealed through a skin test, perhaps 
during a routine check-up. 
If do have active TB disease, may have these symptoms:  
 Overall sensation of feeling unwell.  
 Cough, initially with yellow or green mucus, and possibly with 
bloody sputum later in the disease. 
 Fatigue. 
 Shortness of breath. 
 Weight loss. 
 Fever. 
 Night sweats. 
 Pain in the chest, back or kidneys, or in all three. 
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Figure: 3
(7) 
 
MYCOBACTERIA  (8) 
Kingdom : Bacteria. 
Phylum : Actinobacteria. 
Class     : Actinobacteria. 
Order         : Actinomycetales. 
Suborder : Corynebacterineae. 
Family         : Mycobacteriaceae. 
Genus         : Mycobacterium. 
Species       : Mycobacterium tuberculosis. 
Synonym    : Tubercle bacillus Koch 1882. 
Mycobacterial cell wall:  
The cell wall is a major virulence factor of Mycobacterium 
tuberculosis and contributes to its intrinsic drug resistance. 
(9)
 Cryo-electron 
microscopy showed that the mycobacterial cell wall lipids form an unusual 
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outer membrane. 
(10)
 Identification of the components of the uptake and 
secretion machinery across this membrane is critical for understanding the 
physiology and pathogenicity of Tuberculosis and for the development of 
better anti-tuberculosis drugs.
(11) 
Although the genome of Tuberculosis 
appears to encode over 100 putative outer membrane Proteins, only a few 
have been identified and characterized. The membranes contain Mycolic 
acids, Peptidoglycan, and Arabinogalactan. 
(12) 
Figure 4
(13)  
   
 
GENOME: (14) 
Mycobacterium tuberculosis has circular chromosomes of about 
4,200,000 nucleotides long. The G+C content is about 65%.
 (15)
 
The genome of M. tuberculosis was studied using the strain M. 
tuberculosis H37Rv. The genome contains about 4000 genes. Genes that code 
for lipid metabolism are a very important part of the bacterial genome, and 
8% of the genome is involved in this activity.
 (16) 
The different species of the Mycobacterium tuberculosis complex show 
a 95-100% DNA relatedness based on studies of DNA homology, and the 
sequence of the 16S rRNA gene are exactly the same for all the species. So 
some scientists suggest that they should be grouped as a single species while 
others argue that they should be grouped as varieties or subspecies of  M. 
tuberculosis. 
(17)
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Plasmids in M. tuberculosis are important in transferring virulence 
because genes on the plasmids are more easily transferred than genes located 
on the chromosome. One such 18kb plasmid in the M.tuberculosis 
H37Rv strain was proven to conduct gene transfers.  
Figure 5
(18) 
 
 
LIFECYCLE OF MYCOBACTERIUM TUBERCULOSIS (19) 
The 5 Stages of Tuberculosis are 
1) Onset (1-7 Days): The Bacteria is inhaled.  
2) Symbiosis (7-21 Days): If the Bacteria do not get killed then it 
reproduces. 
3) Initial Caseous Necrosis (14-21 Days): Tuberculosis starts to develop 
when the  Bacteria slow down at reproducing, they kill the surrounding 
nonactivated  Macrophages and run out of cells to divide in. The 
Bacteria then produces anoxic  conditions and reduces the P
H
. The 
Bacteria can't reproduce anymore but can live for  a long time.  
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4) Interplay of Tissue Damaging and Macrophage Activating Immune 
Response (After 21 days): Macrophages surround the tubercle but 
some may be inactive. Tuberculosis then uses it to reproduce which 
causes it to grow. The tubercle can  break off and spread around. If it 
spreads in the blood one can develop tuberculosis  outside the lungs, 
this is called Miliary Tuberculosis.  
5) Liquification and Cavity Formation: The tubercles at one point will 
liquefy,  which will make the disease spread faster, not everyone will 
get to this stage. Only a  small percent of people will get to this stage.  
Figure: 6 
(22) 
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ENZYME PROFILE  
CYCLOPROPANE SYNTHASE CmaA2 
(23)
 
PDB ID        : 1KPI  
Classification : Transferase 
Structure weight : 35797.58  
Molecule : Cyclopropane-fatty-acyl-phospholipid synthase-2 
Polymer  : 1  
Chains : A 
Type : Protein 
Lenth : 302  
Organism : Mycobacterium tuberculosis 
Gene Name : cmaA2 cma2 CMAS-2 Rv0503c MTCY20G9.30c 
The crystal structures of cyclopropane synthase CmaA2 is closely 
related with root mean square deviation (RMSD) between the Ca atoms of the 
core region of less than 0.7Å. The core region which contains a seven 
stranded b-sheet which are all parallel apart from b7 which runs antiparallel. 
The α-helices flank each side of the sheet and run in the same N- to C- 
orientation. The two long α-helices lie adjacent to the C- terminal ends of the 
b-sheet, which encloses SAM/SAH cofactor binding site. In cyclopropane 
synthase the overall polypeptide fold are similar to other SAM-Mtases in the 
protein database, such as catechol-O methyltransferases and DNA 
methyltransferases. 
(24) 
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Figure 7 
(24) 
 
The structure of cyclopropane enzymes is revealed by a tunnel 
approximately 15Å by 10 Å wide which extends from the surface of the 
protein to the cofactor binding site. The tunnel is exclusively lined with 
hydrophobic residues and believed to be the binding site for the acyl substrate 
and is virtually identical in the three enzymes CmaA1, CmaA2 and PcaA. The 
important interactions between the acyl chain and the protein include Leu192, 
Ile169, Phe200, Ile195, Leu205, Leu236, Tyr232, Leu278 and Phe273. It 
reveals that the reactive group may sit in the active binding site and the length 
of the acyl chain which these enzymes may accept apart from the interactions 
of the co-crystal structure with the lipid. 
(25)
              
The cyclopropane synthase CmaA2 and other enzyme are the part of 
FASII pathway for the biosynthesis of mycolic acids in mycobacteria and 
these enzymes acts on a long acyl chain. which linked to acyl carrier protein 
(AcpM). The mechanism for distal versus proximal substrate specificity is 
based on the differing modes of binding of acyl-AcpM. Recent studies shows 
the cyclopropane synthases of M.tuberculosis is considered as a novel class of 
persistence genes and the need of new inhibitors for the persistent phase of 
Introduction 
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tuberculosis infection and the absence of the cyclopropanated lipids in human 
results. 
Cyclopropane synthases as an attractive target for the new drug 
development. Despite the apparent non-redundancy of the CmaA2 and other 
cyclopropane synthases, the similarity of this family of enzymes in the mode 
of binding substrates and in their catalytic mechanism is very clear. This 
makes the prospect of a single drug effectiveness against multiple targets is 
highly possible, so that the chance for the development of drug resistance is 
less. 
(26)
 
NEED FOR NEW DRUGS 
(27) 
The firstline treatment for TB comprises of Rimpampicin, Isoniazid, 
Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, 
delivered under the DOTS programme. The duration of the treatment and the 
side effects of the drugs are major reasons for non-compliance which in return 
catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug 
Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on 
a regimen of drugs which are not only less effective but are also significantly 
more toxic and to top it all have to be administered for extended period up to 
18 months. 
The recent reports of extreme varieties of XDR TB from Mumbai raise 
an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic 
patients, both of which are prevalent in India, make treatment even more 
complex. Thus there is an urgent need to introduce not only new TB drugs but 
also new regiments that are effective and can also reduce the duration of 
therapy.
(27) 
LACK OF INNOVATION 
There is a serious lack of innovation of new drugs in TB as no new 
drugs have been introduced in the last 50 years. This is because of the lack of 
a sizable market attractive for the large pharmaceutical companies to invest. 
The global TB drug market is estimated to be only US$ 300-400 million while 
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the cost of discovery and development of a drug is estimated to be manifolds 
of this figure.
(27)
   
BASIC NUCLEUS INTRODUCTION HETEROCYCLIC 
CHEMISTRY  
Heterocyclic structures always are a part in the field of research and 
development in organic chemistry. Millions of heterocyclic structures are 
found to exist having special properties and biological importance.  
IMIDAZOLE NUCLEUS 
Imidazole is a planer five-member heterocyclic ring with 3C and 2N 
atom and in ring N is present in 1st and 3rd positions. Imidazole derivatives 
have occupied a unique place in the field of medicinal chemistry. The 
incorporation of the imidazole nucleus is an important synthetic strategy in 
drug discovery. 
(28)
 The high therapeutic properties of the imidazole related 
drugs have encouraged the medicinal chemists to synthesize a large number of 
novel chemotherapeutic agents.  
  
BENZIMIDAZOLE NUCLEUS 
Benzimidazole is a heterocyclic aromatic organic compound. This 
bicyclic compound consists of the fusion of benzene and imidazole. The most 
prominent benzimidazole compound nature is N-ribosyl-
dimethylbenzimidazole, which serves as an axial ligand for cobalt in vitamin 
B12.
(29)
 Benzimidazole also has fungicidal properties. It acts by binding to the 
fungal microtubules and stopping hyphal growth. It also binds to the spindle 
microtubules and blocks nuclear division. 
(30)
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BENZOTHIAZOLES
 
Benzothiazoles consist of a 5-membered 1, 3-thiazole ring fused to a 
benzene ring. The nine atoms of the bicycle and the attached substituents are 
coplanar.
(31)
 
Benzothiazole is one of the most important heterocyclic compound, 
weak base, having varied biological activities and still of great scientific 
interest now a days. They are widely found in bioorganic and medicinal 
chemistry with application in drug discovery. 
Benzothiazole is a privileged bicyclic ring system. Due to its potent 
and significant biological activities it has great pharmaceutical importance; 
hence, synthesis of this compound is of considerable interest. The small and 
simple benzothiazole nucleus if present in compounds involved in research 
aimed at evaluating new products that possess interesting biological activities.  
Benzothiazole moites are part of compounds showing numerous 
biological activities such as antimicrobial, anticancer, anthelmintic, anti-
diabetic
 
activities etc, they have also found application in industry as anti -
oxidants, vulcanisations accelerators. Various benzothiazoles such as 2 -
substituted benzothiazole received much attention due to unique structure and 
its uses as radioactive amyloidal imagining agents, and anticancer agents.
(32) 
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On the basis of various literature surveys Imidazole and 
Benzimidazole, Benzthiazole derivatives shows various pharmacological 
activities. 
(33), (34)
 
 Anti-tubercular activity. (35) 
 Anti-fungal and Anti-bacterial activity.   
 Anti-inflammatory activity and analgesic activity.  
 Anti-depressant activity. 
 Anti-cancer activity. (36) 
 Anti-viral activity. 
 Antileishmanial activity.  
On view of the importance of the imidazole and benzimidazole 
nucleus. It was decided to design nucleus based on the imidazole and 
benzimidazole nucleus. Morethan 200 different molecules with the imidazole 
and benzimidazole scaffolds are drawn and docked.  
Aim and Plan of Work 
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AIM AND PLAN OF WORK 
OBJECTIVE OF THE PRESENT STUDY 
AIM 
To develop novel Anti-tubercular molecules, which inhibit 
Cyclopropane mycolic acid synthase-2 (cmaA-2). 
OBJECTIVE 
The Objective of the project is to Design, Synthesis, and Characterize 
and biologically evaluates some novel Anti-tubercular molecules. 
WORK FLOE OF THE STUDY 
 
CYCLOPROPANE MYCOLIC ACID SYNTHASE (cmaA – 2) TARGET 
FROM MEDICINAL CHEMISTRY JOURNALS 
GLIDE / AUTODOCK  
PDB: 1KP 
DOCKING 
FRAGMENT AND 
KNOWLEDGE BASED 
DRUG DESIGN 
PHARMACOPHORE 
20 HITS OF 
DIFFERENT 
ANALOGUES 
CHEMICAL 
AND 
TOXICITY 
PRIORITY GIVEN BASED 
ON SYNTHETIC 
FEASIBILITY AND 
CHEMICAL AVAILABILITY
 Y 
SYNTHESIS 
PURIFIED BY RECRYSTALISATION AND COLUMN CHROMATOGRAPHY 
CHARACTERIZATION BY USING IR, NMR, GC-MS, LC,MS. 
CHARACTERIZATION BY USING IR, NMR, GC-MS, LC, MS 
BIOLOGICAL EVALUATION OF ANTI-TUBERCULAR ACTIVITY BY MABA METHOD. 
LIPINSKI RULE OF FIVE 
Review of Literature 
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REVIEW OF LITERATURE 
The following works throws a light upon the various genomic aspects 
of M.Tuberculosis and also various targets intended for drug action:  
1) De Souza MVN, et al.,(2006)(68) Current status and future prospects 
for new therapies for Pulmonary Tuberculosis. 
2) Duncan k,et al., (2004)(69) Prospects for New Anti-Tubercular drugs.  
Van der Geize,R.et al.,(2007)“AGene Cluster Encoding Cholesterol 
Catabolismin a Soil Actinomycete Provides Insight into 
Mycobacterium Tuberculosis Survival in Macrophages.” 
The review on following works provided basic information about the target 
enzyme, 1KPI and its function: 
3) Maria Loreto Incandela., et al, (2013) reported that 1KPI, a new 
taxonomic marker in mycobacteria. 
(70)
 
4) Liao RZ et al, (1978) Mechanism of Mycolic acid cyclopropane 
synthase. They demonstrated that the reaction starts via the transfer of 
a methyl to the substrate double bond, followed by the transfer of a 
proton from the methyl cation to the bicarbonate present in the active 
site. 
(26)
 
5) George KM, et al., (2008) the biosynthesis of Cyclopropanated 
mycolic acids in Mycobacterium tuberculosis. Identification and 
functional analysis of CMAS-2 revealed the gene whose product 
cyclopropanates the proximal double bond was cloned by homology to 
a putative cyclopropane synthase identified from the Mycobacterium 
leprae genome sequencing project. This gene, named cma2, was 
sequenced and found to be 52% identical to cma1 (which 
cyclopropanates the distal double bond) and 73% identical to the gene 
from M. leprae. Both cma genes were found to be restricted in 
distribution to pathogenic species of mycobacteria. Expression of cma2 
Review of Literature 
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in Mycobacterium smegmatis resulted in the cyclopropanation of the 
proximal double bond in the alpha 1 series of Mycolic acids. 
(71)
 
6) Dominique Guianvarc'h, et al., (2009) Identification of inhibitors of 
the E. coli Cyclopropane fatty acid synthase from the screening of a 
chemical library. 
(72)
 
7) Christine et al. (2007), Synthesis and evaluation of analogues of S-
adenosyl-L-methionine, as inhibitors of the E. coli Cyclopropane fatty 
acid synthase. 
(73) 
8) Cécile Asselineau et al. (2003) reviewed the biosynthesis of Mycolic 
acids by mycobacteria. 
(12)
 
9) Michael S. Glickman et al., (2012) revealed that Mycobacterium 
tuberculosis lacking all Mycolic acid, cyclopropanation is viable but 
highly attenuated and hyper inflammatory in mice. 
(10)
 
10) Chih-chin Huang et al. (2012), Mycolic acids (PcaA, CmaA1, and 
CmaA2) are major components of the cell wall of Mycobacterium 
tuberculosis. Several studies indicate that functional groups in the acyl 
chain of Mycolic acids are important for pathogenesis and persistence. 
(10)
 
The following literatures were surveyed in-depth to provide supporting data 
for the drug design study: 
11) Deepak. D. Borkar., et al. (2012), Design and Synthesis of p-hydroxy 
benzohydrazide Derivatives for their Antimycobacterial Activity. 
(74)
 
12) Romono T. Kroemeret et al.(2003), An introduction into ligand–
receptor docking. It illustrates the basic underlying concepts. 
(75)
 
13) Andrew Worth et al. (1998), Distribution, Metabolism and Excretion 
(ADME) properties, which are often important in discriminating 
between the toxicological profiles of parent compounds and their 
metabolites/degradation products. 
(76)
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14) Lipinski CA et al., (2001) A experimental and computational 
approaches to estimate solubility and permeability in drug discovery 
and development settings. 
(55) 
15) Lipinski CA (2004) A Lead and drug-like compounds and the role of 
fine resolution. 
(56)
  
16) Madsen et al., (2002) Textbook of Drug Design and Discovery. (77) 
The review on following works provided ideas for synthesis of the desired 
benzothiazole nucleous for anti tubercular agents:  
17) RuhiAli  and NadeemSiddiqui Journal of Chemistry 
Volume 2013 (2013), Article ID 345198, 12 pages http://dx.doi.org/ 
10.1155/2013/345198  Indian journal of pharmaceutical sciences. 
Review Article:  Biological Aspects of Emerging Benzothiazoles: A 
Short Review
(78) 
18) S. T. Asundaria and K. C. Patel, “Synthesis, characterization and 
antimicrobial activity of thiazole, benzothiazole and pyrimidine 
derivatives bearing sydnone moieties,”  Pharmaceutical Chemistry 
Journal, vol. 45, no. 12, pp. 725–731, 2012(79) 
19) K. Bolelli, I. Yalcin, T. Ertan-Bolelli et al., “Synthesis of novel 2-[4-
(4-substitutedbenzamido/phenylacetamido) phenyl]benzothiazoles as 
antimicrobial agents,” Medicinal Chemistry Research, vol. 21, no. 11, 
pp. 3818–3825, 2012(80) 
20) P. K. Sharma, M. Kumar, and V. Mohan, “Synthesis and 
antimicrobial activity of 2H-pyrimido[2,1-b]benzothiazol-2- 
ones,” Research on Chemical Intermediates, vol. 36, no. 8, pp. 985–
993, 2010.  (81) 
21) C. Sheng, J. Zhu, W. Zhang et al., “3D-QSAR and molecular docking 
studies on benzothiazole derivatives as Candida albicans N-
myristoyltransferase inhibitors,” European Journal of Medicinal 
Chemistry, vol. 42, no. 4, pp. 477–486, 2007..(82)  
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22) B. S. Soni, M. Ranawat, R. Sharma, A. Bhandari, and S. Sharma, 
“Synthesis and evaluation of some new benzothiazole derivatives as 
potential antimicrobial agents,” European Journal of Medicinal 
Chemistry, vol. 45, no. 7, pp. 2938–2942, 2010(83) 
23) P. K. Sahu, P. K. Sahu, S. K. Gupta, D. Thavaselvam, and D. D. 
Agarwal, “Synthesis and evaluation of antimicrobial activity of 4H-
pyrimido[2,1-b] benzothiazole, pyrazole and benzylidene derivatives of 
curcumin,” European Journal of Medicinal Chemistry, vol. 54, pp. 
366–378, 2012 (84) 
24) I. H. R. Tomi, J. H. Tomma, A. Daraji, and A. Al-Dujaili, 
“Synthesis, characterization and comparative study the microbial 
activity of some heterocyclic compounds containing oxazole and 
benzothiazole moieties,” Journal of Saudi Chemical Society, 2012(85) 
25) V. S. Padalkar, B. N. Borse, V. D. Gupta et al., “Synthesis and 
antimicrobial activity of novel 2-substituted benzimidazole, 
benzoxazole and benzothiazole derivatives,”  Arabian Journal of 
Chemistry, 2012.
(86)  
 
26) S. Gilani, K. Nagarajan, S. P. Dixit, M. Taleuzzaman, and S. A. 
Khan, “Benzothiazole incorporated thiazolidin-4-ones and azetidin-2-
ones derivatives: synthesis and in vitro antimicrobial 
evaluation,”Arabian Journal of Medicinal Chemistry, 2012.(87)    
27) Arpana Rana, N Siddiqui, SA Khan Year : 2007  Volume : 69  
|  Issue : 1 Page : 10-17  Benzothiazoles: A new profile of biological 
activities(88) 
28) G. Navarrete-Vazquez, M. Ramírez-Martínez, S. Estrada-Soto et 
al., “Synthesis, in vitro and in silicoscreening of ethyl 2-(6-substituted 
benzo[d]thiazol-2-ylamino) -2-oxoacetates as protein-tyrosine 
phosphatase 1B inhibitors,” European Journal of Medicinal Chemistry, 
vol. 53, pp. 346–355, 2012.(89) 
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29) G. A. Pereira, A. C. Massabni, E. E. Castellano et al., “A broad 
study of two new promising antimycobacterial drugs: Ag(I) and Au(I) 
complexes with 2-(2-thienyl)benzothiazole,” Polyhedron, vol. 38, no. 
1, pp. 291–296, 2012 ·(90)  
30) V. N. Telvekar, V. K. Bairwa, K. Satardekar, and A. Bellubi, 
“Novel 2-(2-(4-aryloxybenzylidene) hydrazinyl)benzothiazole 
derivatives as anti-tubercular agents,” Bioorganic and Medicinal 
Chemistry Letters, vol. 22, no. 1, pp. 649–652, 2012.(91)  
31) L. Katz, “Antituberculous compounds. III. Benzothiazole and 
benzoxazole derivatives,” Journal of the American Chemical Society, 
vol. 75, no. 3, pp. 712–714, 1953(92) 
32) Y. Cho, T. R. Ioerger, and J. C. Sacchettini,  “Discovery of novel 
nitrobenzothiazole inhibitors forMycobacterium tuberculosis  ATP 
phosphoribosyl transferase (HisG) through virtual screening,”  Journal 
of Medicinal Chemistry, vol. 51, no. 19, pp. 5984–5992, 2008. (93) 
33) Kamuran Görgün, Handan Can Sakarya, and Müjgan Özkütük The 
Synthesis, Characterization, Acid Dissociation, and Theoretical 
Calculation of Several Novel Benzothiazole Schiff Base Derivatives J. 
Chem. Eng. Data, 2015, 60 (3), pp 594–601(94) 
34) Mahmood-ul-Hassan a, Zahid H. Chohanb* & Claudiu T. Supuran 
Anti Bacterial Co(Ii) And Ni(Ii) Complexes Of Benzothiazole-Derived 
Schiff Bases  DOI:10.1081/SIM-120014861   c    pages 1445-1461 
Article from Tayler And Francies Online (95) 
35) Vaibhav Sharma et al [38] reviewed on the chemistry and biological 
activities of Schiff base. Schiff bases are the compounds which are 
mainly formed by the condensation of the aldehydes and amines. These 
compounds can be synthesized by various synthetic routes. 
Pharmacological actions of Schiff compounds which have been 
reported in previous studies are antimicrobial, antimalarial, 
antitubercular, anticancer, anthelmintic, analgesic, etc. 
(96)
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36) Khlood Fahed Hamak synthesized Schiff base and evaluated it for 
antimicrobial activity. Schiff base were synthesis by the reaction of 
2,6-bis(4-chlorophenyl)piperidone-4 with benzidine and reaction of 
3,5-dimehyl-2,6-diphenyl piperidone-4 with 1,2-phenylenediamine. All 
synthesized compound were characterized and evaluated for their in 
vitro antibacterial activities, against gram positive (Staphylococcus 
aureus) and gram negative (Escheria coli).
(97) 
 
 
37) Kalpesh S. Parikh et al., designed and synthesized Schiff bases from 
acetophenone. 6-amino imidazole Condensed with various aromatic 
acetophenone. Finally the product was characterized by conventional 
and instrumental methods. 
(98)
 
 
38) Micheal J. Hearn et al  synthesized and characterized Schiff base of 
isoniazid and studied their biological activity. Few structural 
modification of the isonicotinic acid hydrazide (INH) was performed 
which provides lipophilic adaptations of the drug in which the 
hydrazine moiety of the parent compound has been chemically blocked 
from the deactivating process of N2-acetylation by N-aryl amino acetyl 
transferase. 
The review on following works revealed the basics of Alamar blue assay for 
evaluating the anti-mycobacterial action  
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39) David A. J. Moore., et al., (2008), Inter- and Intra-Assay 
Reproducibility of Microplate Alamar Blue Assay Results for 
Isoniazid, Rifampicin,Ethambutol, Streptomycin, Ciprofloxacin, and 
Capreomycin Drug Susceptibility Testing of Mycobacterium 
tuberculosis. 
(64), (66), (67)
  
40) Todd P. Primm., et., al(2007), Recent Advances in Methodologies for 
the Discovery of Antimycobacterial Drugs. 
(99)
 
41) Sephra N.Ramprasad [71] studied the various applications of Alamar 
blue as an indicator. Alamar blue is an indicator that is used to 
evaluated metabolic function and cellular health. The Alamar blue 
bioassay is being utilized to access cell viability and cytotoxicity in a 
biological and environmental system and in a number of cell types 
including bacteria, yeast, fungi, and protozoa.
(100) 
 
42) Jose d Jesus Alba-Romero et al [72] applied the Alamar blue assay to 
determine the susceptibility to anti-tuberculosis pharmaceuticals. The 
results showed that the MABA test is fast and easy to apply. It is very 
reliable method to determining the drug susceptibility to  
pharmaceuticals.
(101) 
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MATERIALS AND METHODS 
The Project is to be carried out in the following phases.  
 Drug design by using Argus lab. 
 Synthesis of the designed molecules.  
 Characterization of the synthesized molecules.  
 Biological evaluation of the synthesized molecules.  
DOCKING STUDIES DRUG DESIGN:
(37) 
Drug design, sometimes referred to as rational drug design or 
simply rational design, is the inventive process of finding new medications 
based on the knowledge of a biological target.
(38)
 The drug is most commonly 
an organic small molecule that activates or inhibits the function of 
a biomolecule such as a protein, which in turn results in a therapeutic benefit 
to the patient. In the most basic sense, drug design involves the design of 
molecules that are complementary in shape and charge to the biomolecular 
target with which they interact and therefore will bind to it.  
Drug design frequently but not necessarily relies oncomputer 
modeling techniques.
(39)
 This type of modeling is often referred to 
as computer-aided drug design. Finally, drug design that relies on the 
knowledge of the three-dimensional structure of the biomolecular target is 
known as structure - based drug design.
(39)
 In addition to small molecules, 
biopharmaceuticals and especially therapeutic antibodies are an increasingly 
important class of drugs and computational methods for improving the 
affinity, selectivity, and stability of these protein-based therapeutics have also 
been developed.
(40)
 
Drug design with the help of computers may be used at any of the 
following stages of drug discovery:  
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1) Hit identification using virtual screening (structure- or ligand-based 
design) 
2) Hit-to-lead optimization of affinity and selectivity (structure-based 
design, QSAR, etc.) 
3) Lead optimization optimization of other pharmaceutical properties 
while maintaining affinity 
TYPES 
There are two major types of drug design. The first is referred to 
as ligand-based drug design and the second, structure-based drug 
design.
(39)
  
Ligand-based 
Ligand-based drug design (or indirect drug design) relies on 
knowledge of other molecules that bind to the biological target of interest. 
These other molecules may be used to derive a pharmacophore model that 
defines the minimum necessary structural characteristics a molecule must 
possess in order to bind to the target.
(41)
  
Structure-based 
Structure-based drug design (or direct drug design) relies on 
knowledge of the three dimensional structureof the biological target obtained 
through methods such as x-ray crystallography or NMR spectroscopy.
(42)
 If an 
experimental structure of a target is not available, it may be possible to create 
a homology model of the target based on the experimental structure of a 
related protein. Using the structure of the biological target, candidate drugs 
that are predicted to bind with high affinity and selectivity to the target may 
be designed using interactive graphics and the intuition of a  medicinal 
chemist. Alternatively various automated computational procedures may be 
used to suggest new drug candidates.
(43)
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Binding site identification 
Binding site identification is the first step in structure based 
design.
(44),(45)
 If the structure of the target or a sufficiently similar  homolog is 
determined in the presence of a bound ligand, then the ligand should be 
observable in the structure in which case location of the binding site is trivial. 
However, there may be unoccupied allosteric binding sites that may be of 
interest. Furthermore, it may be that only apoprotein (protein without ligand) 
structures are available and the reliable identification of unoccupied sit es that 
have the potential to bind ligands with high affinity is non-trivial. 
Scoring functions 
Structure-based drug design attempts to use the structure of proteins as 
a basis for designing new ligands by applying the principles of  molecular 
recognition. Selective high affinity binding to the target is generally desirable 
since it leads to more efficacious drugs with fewer side effects. Thus, one of 
the most important principles for designing or obtaining potential new ligands 
is to predict the binding affinity of a certain ligand to its target (and 
known antitargets) and use the predicted affinity as a criterion for 
selection.
(46)
  
One early general-purposed empirical scoring function to describe the 
binding energy of ligands to receptors was developed by Bohm.
(47),(48)
 This 
empirical scoring function took the form: 
 
where: 
 ΔG0 – empirically derived offset that in part corresponds to the overall 
loss of translational and rotational entropy of the ligand upon binding.  
 ΔGhb – contribution from hydrogen bonding 
 ΔGionic – contribution from ionic interactions 
 ΔGlip – contribution from lipophilic interactions where |A lipo| is surface 
area of lipophilic contact between the ligand and receptor  
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 ΔGrot – entropy penalty due to freezing a rotatable in the ligand bond 
upon binding 
Figure 1 
(49) 
 
STEPS INVOLVED IN DOCKING 
(50), (51), (52)
 
Docking is done by using ARGUS LAB Software 
 Protein preparation. 
 Selection of active site (Q-Site finder). 
 Ligand Preparation. 
 Docking Procedure. 
 Visualization / Interpretation of Docking.  
PROTEIN PREPARATION 
Step: 1  
 Protein (pdb) ID is entered in the protein data bank. (1KPI)  
 I clicked the download files and select pdb as text file.  
 Saved the downloaded pdb (text file) to the desktop.  
Step: 2  
 After I Opened Argus lab fileOpenImported pdb file from the 
desktop. 
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 3D Structure of the protein will appeared in the workspace of Argus lab.  
 Left side of the screen shows molecular tree view.  
 Open pdb  Open ‘residues’  Open ‘misc’ 
 From ‘Misc’ delete the inhibitor and hetero residues [Note: Do not 
delete Co-factor]  
 Then I  Opened water press shift, selected all water molecules and 
deleted. 
 Added hydrogen atoms.  
 Go to Calculation on the toolbar  energy by UFF method  start. 
 Saved the prepared protein as *.agl file format in the desktop.  
2. Q-SITE FINDER 
Step: 1  
 Open Q-Site finder through online. 
 Upload / Import the PDB format of the Protein 
 Find all the active site and make a list out of the common amino acid 
residues. 
 Step: 2  
 Open residues  open  Amino acids.  
 Press control and select the amino acid Which were listed from the Q-
Site finder.  
 Make sure that all amino acid residues listed are selected.  
 Right click on the mouse make a group from the selected residues give 
name Binding site Ok. 
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 3. LIGAND PREPARATION  
 Draw the structure from Chem sketch and save as MDL Mol format.  
 Imported the ligand into workspace of Argus lab.  
 Cleaned Geometry, Cleaned Hybridisation.  
 I Selected the ligand, Right click on the mouse Make a group from the 
residues give name ligand Ok. 
4. DOCKING PROCEDURE 
 Selected the set up a Dock Ligand calculation from the toolbar.  
 Argus Dock as the Docking Engine.  
 Dock was selected as calculation type.  
 Flexible for the scoring function.  
 Calculation size.  
 Start docking. 
 Saved the Docked protein Ligand complex as Brookhaven pdb files 
(*.pdb) 
5. VISUALIZATION / INTERPRETATION OF DOCKING 
Molegro Molecular viewer will help in analysing the energies and 
interaction of the binding.  
 View  Secondary Structure view.  
 View  Hydrogen bond interaction. 
 Ligand map  Interaction overlay. 
TOXICITY PREDICTION 
All the data set molecules were subjected to the toxicity risk 
assessment by using Osiris program, which is available online. The OSIRIS 
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property Explorer shown in this page is an integral part of Actelion's in house 
substance registration system. It allows drawing chemical structures and also 
calculates various drug relevant properties whenever a structure is valid.  
Prediction results are color coded in which the red color shows high 
risks with undesired effects like mutagenicity or a poor intestinal absorption 
and green color indicates drug-conform behavior. 
[54] 
Molecular property prediction includes 
 Toxicity risk assessment 
 Clog P prediction 
 Solubility prediction 
 Molecular weight 
 Drug likeness prediction 
 Drug likeness score 
LIPINSKI’S RULE OF FIVE (55), (56)  
 Lipinski's rule of five also known as the Pfizer's rule of five or 
simply the Rule of five (RO5) is to evaluate druglikeness or determine 
if a chemical compound with a certain pharmacological or biological 
activity has properties that would make it a likely orally active drug in 
humans.  
 The rule was formulated by Christopher A.Lipinski in 1997. The rule 
describes molecular properties important for a drug’s pharmacokinetics 
in the human body, including their absorption, distribution, 
metabolism, and excretion ("ADME"). However, the rule does not 
predict if a compound is pharmacologically active.   
 Lipinski's rule states that, in general, an orally active drug has no more 
than one violation of the following criteria: 
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Figure 2 
(57)
 
 
SYNTHETIC METHODOLOGY 
Scheme 
Ar
-
CHO + Ar
-
NH2
Ar
-
CH
N Ar
-
Aromatic
   Aldehyde
Aromatic 
     Amine Schiff Base
-H2O
 
Synthesis of Schiff base  
Equimolar quantity of 6-nitro-1H-benzimidazol-2-amine and 
substituted aromatic aldehydes is reflux for 10-15 hours in 20ml of ethanol. 
Completion of the reaction is monitor by TLC. After the completion of the 
reaction, the mixture was pour into a beaker containing ice cold water. The 
precipitate is form then filter the precipitate and dry it. The product is 
recrystallize by using ethanol. 
[58]
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REACTANT PROFILE  
N NH2
CH3
 
MOLECULAR FORMULA : C6H8N2 
MOLECULAR WEIGHT : 108.14 
BOILING POINT : 230
0
C 
MELTING POINT : 96-99
0
C 
BENZYLOXY BENZALDEHYDE 
O
CHO
 
MOLECULAR FORMULA : C14H12O 
MOLECULAR WEIGHT : 212.24 
MELTING POINT : 70-72
0
C 
p-TOLUDINE 
CH3
NH2  
MOLECULAR FORMULA : C7H9N 
MOLECULAR WEIGHT : 107 
BOILING POINT : 200
0
C 
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2-HYDRAZINO BENZOYHIAZOLE 
N
S
NH
NH2 
MOLECULAR FORMULA : C7H7N3S 
MOLECULAR WEIGHT : 165. 
MELTING POINT : 198-202
0
C 
2, 4 DICHLORO BENZALDEHYDE 
Cl
Cl
CHO  
MOLECULAR FORMULA : C7H4Cl2O 
MOLECULAR WEIGHT : 175.01 
BOILING POINT : 233
0
C 
MELTING POINT : 64-69
0
C 
CHARACTERIZATION PHYSICAL EVALUATION:  
1) Physical properties of the synthesized compounds are evaluated, such as 
 Nature  
 Solubility  
 Molecular formula  
 Melting point  
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 Boiling point  
 Colour   
 Molecular weight  
2) Further the synthesized compounds are Characterized by following 
Spectroscopic methods. Such as 
IR SPECTROSCOPY
(59) 
Infrared (IR) spectroscopy is one of the most common spectroscopic 
techniques used by organic chemists. The main goal of IR spectroscopic 
analysis is to determine the chemical functional groups in the sample. 
Different functional groups absorb characteristic frequencies of IR radiation. 
IR spectroscopy is an important and popular tool for structural elucidation 
and compound identification. The possible characteristic bands of the nucleus 
are  
 3540-3300 cm-1 N-H Stretching Vibration  
 3670-3230 cm-1 O-H Stretching Vibration  
 1690-1630 cm-1 C=N Stretching Vibration  
 2975-2840 cm-1 C-H Aliphatic Stretching Vibration  
 3100-3000 cm-1 C-H Aromatic Stretching Vibration 
NMR SPECTROSCOPY
(60) 
NMR is the most powerful analytical tool currently available to an 
organic chemist. NMR allows characterization of a very small amount of 
sample (10mg), and does not destroy the sample (non-destructive technique). 
NMR spectra can provide vast information about a molecule's structure and 
can very often be the only way to prove what the compound really is. 
Typically though, NMR is used in conjunction with other types of 
spectroscopy and chemical analysis to fully confirm a complicated molecule's 
structure. It involves the interaction of the electromagnetic radiation and the 
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hydrogen of the nucleus when placed in an external static magnetic field. 
Some basic characteristic peaks of the nucleus  
 Aromatic and hetero aromatic compounds 6-8.5 δ  
 Alcoholic hydroxyl protons 1-5.5 δ  
 Aldehyde protons 9-10 δ  
 
MASS SPECTROSCOPY
(61) 
Mass Spectrometry is an analytic technique that utilizes the degree of 
deflection of charged particles by a magnetic field to find the relative masses 
of molecular ions and fragments. It is a powerful method because it provides 
a great deal of information and can be conducted on tiny samples. Mass 
spectrometry has a number of applications in organic chemistry. They are:  
 Determining molecular mass  
 Finding out the structure of an unknown substance  
 Verifying the identity and purity of a known substance  
 Providing data on isotopic abundance 
HYPHENATED TECHNIQUE
(62),(63) 
1.GC-MS  
It is a combined technique, used for molecular weight determination. 
Gas chromatography and mass spectroscopy combined to form GC-MS.  
2.LC-MS: 
LC-MS is an analytical chemistry technique that combines with 
physical seperation capabilities of liquid chromatography with mass analusis 
capabilities of mass chromatography. It has very high sensitivity.  
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BIOLOGICAL EVALUATION 
Anti-tubercular Activity 
There are various high throughput assays available for screening of 
new chemical entities against tuberculosis. They are:  
 Micro plate Alamar Blue Assay  
 BACTEC Assay  
 Luciferous Reporter Phage assay  
 REMA Assay  
 Broth Dilution Assay  
 Middle brook(7H 9,7H 10,7H 11) Agar Dilution Assay.  
THE ALAMAR BLUE ASSAY  
Alamar Blue monitors the reducing environment of the living cell. The 
active ingredient is resazurin (IUPAC name: 7-hydroxy-10-oxidophenoxazin-
10-ium-3-one), also known as diazoresorcinol, azoresorcin, resazoin, 
resazurine, which is water-soluble, stable in culture medium, is non-toxic and 
permeable through cell membranes. Continuous monitoring of cells in culture 
is therefore permitted. Growth is measured quantitatively by a visual colour 
change and the amount of fluorescence produced is proportional to the 
number of the living cells which is determined by colorimetric and 
fluorimetric methods.
(64) 
APPLICATIONS  
 Especially meant for studies on Mycobacterium tuberculosis.  
 Used extensively in cell viability and cytotoxicity studies. (65) 
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PROCEDURE for Anti-TB activity using Alamar Blue Dye
(66),(67) 
 The anti-mycobacterial activity of compounds were assessed against 
M. tuberculosis      using microplate Alamar Blue assay (MABA).  
 This methodology is non-toxic, uses a thermally stable reagent and 
shows Good correlation with propotional and BACTEC radiometric 
method 
 Briefly, 200μl of sterile deionzed water was added to all outer 
perimeter Wells Of sterile 96 wells plate to minimized evaporation of 
medium in the test wells during incubation.  
 The 96 wells plate received 100 μl of the Middlebrook 7H9 broth and 
serial dilution of compounds were made directly on plate.  
 The final drug concentrations tested were 100 to 0.2 μg/ml.  
 Plates were covered and sealed with parafilm and incubated at 37ºC for 
five days. 
 After this time, 25μl of freshly prepared 1:1 mixture of Almar B lue 
reagent And 10% tween 80 was added to the plate and incubated for 24 
hrs.  
 A blue color in the well was interpreted as no bacterial growth, and 
pink Color was scored as growth.  
 The MIC was defined as lowest drug concentration which prevented 
the Color change from blue to pink. 
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RESULT AND DISCUSSION 
Two hundred molecules which were sketched using chemsketch.® 
Then it were docked against the MTB enzyme cyclopropane mycolic acid 
synthase 2 by using Argus lab 4.0.1® softwere. The molecules with best 
docking score and good interaction were selected and synthesised.  
   The molecules were also docked against the following targets,  
 Oxidoreductase (4TRM)  
 Cyclopropane fatty acid synthase (3HEM) 
 Thymidilate synthase (3GWC)   
The resultant scores are tabelled below, 
Table No: 1 
Name of the targets 
Docking scores(kcal/mol) 
M1 M2 M3 M7 M11 
cyclopropane mycolic acid 
synthase 2(1KPI) 
-10.5407 -9.79903 -8.445 
 
-11.140 -9.2508 
Oxidoreductase (4TRM),  -9.6345 -6.1127 -5.875 -10.664 7.6654 
Cyclopropane fatty acid 
synthase (3HEM) 
-8.6543 -5.6759 -11.564 -8.4538 -9.876 
Thymidilate synthase (3GWC -9.9983 -11.7685 -7.560 -6.0029 -4.9876 
 
Result and Discussion 
College of Pharmacy, MMC, Chennai-3. Page No.39 
Interaction of the docked molecules with the enzyme cyclopropane 
mycolic acid synthase 2 (1KPI) 
 
 
 
 
M1 
 
 
        
Cl
ClN
NH
SN
 
-10.5407 
kcal/mol 
 
 
M2 
 
 
 
 
Cl
Cl
N
N
CH3 
-9.79903 
kcal/mol 
 
 
M3 
 
     
N
S
N
NCH3
CH3  
-8.445 
kcal/mol 
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M7                                   
O
N
NH
N
S
 
 
-11.1405 
kcal/mol 
 
M11 CH3
N
N
CH3
CH3
 
-9.2508 
kcal/mol 
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TABLE 1: 1KPI INTERACTION WITH LIGAND 
S.NO 
INTERACTION WITH AMINO 
ACIDS 
HYDROGEN BOND 
INTERACTION 
M1 
  
M2 
  
M3 
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M7 
  
 
 
 
M11 
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PHYSIO CHEMICAL PROPERTIES OF SYNTHESISED 
SAMPLES 
SAMPLE CODE: M1 
IUPAC: 2-[(2E)-2-(2,4-dichlorobenzylidene)hydrazinyl]-1,3-benzothiazole 
Cl
Cl
N
NH
S
N
 
Molecular Formula : C14H9Cl2N3S 
Formula Weight : 322.21236 
Appearance : light yellow 
Melting  point : 230
0
C 
Solubility         : Methanol, Chloroform, Ethyl acetate  
Composition : C (52.19%) H (2.82%) Cl (22.01%) N (13.04%) 
S (9.95%) 
Molar Refractivity  : 85.59 ± 0.5 cm
3
 
Molar Volume  : 219.7 ± 7.0 cm
3 
Parachor  :  596.9 ± 8.0 cm
3
 
Index of Refraction  : 1.707 ± 0.05 
Surface Tension  : 54.4 ± 7.0 dyne/cm 
Density  : 1.46 ± 0.1 g/cm
3
 
Surface Tension  : 40.9 ± 7.0 dyne/cm 
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SAMPLE CODE: M2 
IUPAC: (E)-1-(2,4-dichlorophenyl)-N-(4-methylpyridin-2-yl)methanimine 
Cl
Cl
N
N
CH3 
Molecular Formula : C13H10Cl2N2 
Formula Weight    : 265.1379 
Composition      : C(58.89%) H(3.80%) Cl(26.74%) N(10.57%) 
Appearance     : light yellow 
Melting point      : 900C 
Solubility     : Methanol, Chloroform, Ethyl acetate 
Molar Refractivity : 72.48 ± 0.5 cm3 
Molar Volume : 212.0 ± 7.0 cm3 
Parachor  : 536.3 ± 8.0 cm3 
Index of Refraction  : 1.599 ± 0.05   
Polarizability     : 28.73 ± 0.5 10-24cm3  
Density  : 1.25 ± 0.1 g/cm3 
Polarizability  : 33.93 ± 0.5 10-24cm3 
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SAMPLE CODE: M3 
IUPAC: 4-[(Z)-(1,3-benzothiazol-2-ylimino)methyl]-N,N-dimethylaniline 
N
S
N
NCH3
CH3  
Molecular Formula : C16H15N3S 
Formula Weight  : 281.3754 
Composition  : C(68.30%) H(5.37%) N(14.93%) S(11.40%) 
Appearance         : light yellowish colour 
Melting point      : 2300C 
Solubility           : Methanol, Chloroform, Ethyl acetate 
Molar Refractivity : 86.14 ± 0.5 cm3 
Molar Volume : 237.6 ± 7.0 cm3 
Parachor  : 615.8 ± 8.0 cm3 
Index of Refraction : 1.644 ± 0.05   
Surface Tension : 45.0 ± 7.0 dyne/cm 
Density  : 1.18 ± 0.1 g/cm3 
Polarizability    : 34.14 ± 0.5 10-24cm3 
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SAMPLE CODE: M7 
IUPAC: 2-{(2E)-2-[4-(benzyloxy) benzylidene] hydrazinyl}-1, 3-benzothiazole 
O
N
NH
S N
 
Molecular Formula : C21H17N3OS 
Formula Weight  : 359.44418 
Composition         : C(70.17%) H(4.77%) N(11.69%) O(4.45%) 
S(8.92%) 
Appearance         : Light brown colour 
Melting point      : 2700C 
Solubility         : Methanol, Chloroform, Ethyl acetate 
Molar Refractivity : 107.49 ± 0.5 cm3 
Molar Volume    : 291.6 ± 7.0 cm3 
Parachor  : 773.9 ± 8.0 cm3 
Index of Refraction  : 1.658 ± 0.05   
Surface Tension : 49.5 ± 7.0 dyne/cm 
Density  : 1.23 ± 0.1 g/cm3 
Polarizability  : 42.61 ± 0.5 10-24cm3 
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SAMPLE CODE: M11 
IUPAC: N, N-dimethyl-4-{(E)-[(4-methylphenyl)imino]methyl}aniline 
CH3
N
NCH3
CH3  
Molecular Formula  : C16H18N2 
Formula Weight    : 238.32752 
Composition  : C (80.63%) H (7.61%) N (11.75%) 
Appearance       : Dark yellow 
Melting point        : 1100C 
Solubility         : Methanol, Chloroform, Ethyl acetate 
Molar Refractivity : 77.63 ± 0.5 cm3 
Molar Volume       : 246.0 ± 7.0 cm3 
Parachor  : 593.8 ± 8.0 cm3 
Index of Refraction   : 1.543 ± 0.05   
Surface Tension : 33.9 ± 7.0 dyne/cm 
Density  : 0.96 ± 0.1 g/cm3 
Polarizability : 30.77 ± 0.5 10-24cm3 
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IR SPECTRUM 
The samples were prepared by the KBr pellet techniques & spectrum 
obtained by using FT-IR SHIMADZU. 
The spectra were examined for the absence of the functional groups of 
the parent compounds and for presence of the vibrational absorption band for 
the new functional group. 
The reaction involves between the aldehydes and amines to give the 
yield of Schiff base. Therefore it is expected that there should be no 
absorption band corresponding to either the aldehyde or the amine.  
An absorption band corresponding to C=N stretching -1550-1680cm
-1
. 
Table No: 2 
Absorption bands M1 M2 M3 M4 M5 
Aldehydes X X X X X 
Amines X X X X X 
C=N      
() - Indicates presence of functional groups 
(X) - Indicates absence of functional groups 
SAMPLE CODE: M1 
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SAMPLE CODE: M2 
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SAMPLE CODE: M7 
 
 
SAMPLE CODE: 11 
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LC-MS SPECTRUM 
The molecular weight of synthesised compounds are compared by 
using LC-MS Spectrum. 
LC-MS results. 
Table No: 3 
SAMPLES 
CALCULATED 
MASS 
ACTUAL MASS OF SYNTHESIZED 
COMPOUND 
M1 322.2123 g/mol 321.9984 g/mol 
M2 265.1329 g/mol 265.0306 g/mol 
M3 281.3754 g/mol 282.1063 g/mol 
M7 359.4441 g/mol 360.1167 g/mol 
M11 238.3275 g/mol 239.1555 g/mol 
SAMPLE CODE: M1 
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SAMPLE CODE:M2 
 
 
SAMPLE CODE:M3 
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SAMPLE CODE:M7 
 
 
SAMPLE CODE:M11 
 
 
Result and Discussion 
College of Pharmacy, MMC, Chennai-3. Page No.54 
GC-MS SPECTRUM 
The molecular weight of synthesised compounds are compared with the 
GC-MS results.  
Table No: 4 
SAMPLES 
CALCULATED 
MASS 
ACTUAL MASS OF SYNTHESISED 
COMPOUNDS 
M1 322.21 g/mol 321.1360 g/mol 
M2 265.13 g/mol 265.1512 g/mol 
SAMPLE CODE:M1 
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SAMPLE CODE: M2 
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NMR SPECTRUM 
Our synthesised compounds were subjected to H
1
 NMR instruments. 
Then the compounds are characterised by using NMR spectrum. 
SAMPLE CODE: M3 
 
 
Table No: 5 
TYPE OF PROTON NO. OF PROTON δ  VALUES 
Aromatic C-H 7 7.5 
Benzylidene N=CH 1 8.0 
NH 1 3.5 
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SAMPLE CODE:M7 
 
 
TYPE OF PROTON NO. OF PROTON δ  VALUES 
Aromatic C-H 13 7.0-8.0 
NH 1 3.5 
CH2 2 5.0 
Benzylidene N=CH 1 8.1 
 
Result and Discussion 
College of Pharmacy, MMC, Chennai-3. Page No.58 
SAMPLE CODE:M11 
 
 
Table No: 6 
TYPE OF PROTON NO. OF PROTON δ  VALUES 
N(CH3) 6 3.1 
CH3 3 2.3 
Aromatic (C-H) 8 6.5-8.0 
C-H 1 3.1 
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TOXICITY STUDIES 
Toxicity predicted by the OSIRIS Property Explorer the online 
software of Thomas Sander, Actelion Pharmaceuticals Ltd., Gewerbestrasse 
16, and 4123 Allschwil, Switzerland. The OSIRIS Property Explorer shown in 
this page is an integral part of Actelion's (1) inhouse substance registration 
system. It lets you draw chemical structures and calculates on-the-fly various 
drug-relevant properties whenever a structure is valid. Prediction results are 
valued and colour coded. Properties with high risks of undesired effects like 
mutagenicity or a poor intestinal absorption are shown in red. Whereas a 
green colour indicates drug conform behaviour. 
Table No: 7 
SAMPLES M1 M2 M3 M7 M11 
MUTAGENIC      
TUMORIGENIC  X  X  
IRRITANT      
REPRODUCTIVE EFFECT      
 () - Indicates absence of toxicity 
 (X) - Indicates presence of toxicity 
SAMPLE CODE: M1 
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SAMPLE CODE: M2 
 
 
SAMPLE CODE: M3 
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SAMPLE CODE: M7 
 
 
SAMPLE CODE: M11 
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BIOLOGICAL EVALUATION: 
Anti TB results 
Table No: 8 
S. 
No 
Samples 
100 
µg/ml 
50 
µg/ml 
25 
µg/ml 
12.5 
µg/ml 
6.25 
µg/ml 
3.12 
µg/ml 
1.6 
µg/ml 
0.8 
µg/ml 
1. M1 S R R R R R R R 
2. M2 S S R R R R R R 
3. M3 S S R R R R R R 
4. M7 R R R R R R R R 
5. M11 S R R R R R R R 
Note: 
S - Sensitive  
R - Resistant  
 Strain used: M.tuberculosis (H37 RV strain).  
 Here are the standard values for the Anti-Tb test which was performed.  
 Pyrazinamide- 3.125μg/ml.  
 Streptomycin- 6.25μg/ml.  
 Ciprofloxacin- 3.125μg/ml. 
Table No: 9 
Sample code Docking score Mic values 
M1 -10.5407kcal/mol 100 µg/ml 
M2 -9.79903kcal/mol 50 µg/ml 
M3 -8.4453kcal/mol >100 µg/ml 
M7 -11.1405kcal/mol 50 µg/ml 
M11 -9.2508kcal/mol 100 µg/ml 
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SAMPLE DRUG PHOTOGRAPH 
S. 
No 
Samples 
100 
µg/ml 
50 
µg/ml 
25 
µg/ml 
12.5 
µg/ml 
6.25 
µg/ml 
3.12 
µg/ml 
1.6 
µg/ml 
0.8 
µg/ml 
1. M1 
 
2. M2 
3. M3 
4. M7 
5. M11 
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DISCUSSION 
 I have synthesised five different compounds of Schiff bases.  The basic 
level of purity confirmation done by Melting point and TLC.  
 Then I confirmed the synthesised compounds by various spectrums.  
 After that I gone for the toxicity studies. In that only M3 and M11 
compounds were have tumorigenic and rest of the synthesised 
compounds were non-toxic. 
 Despite the compounds has best docking score, the resistant would be 
formed at the level of 25-50 µg/ml. 
 In that M7 also has good docking score but it doesn’t have sensitive 
even at the level of 100µg/ml.  
Summary and Conclusion 
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SUMMARY AND CONCLUSION 
 Cyclopropane Mycolic acid Synthase-2 (1KPI) a critical enzyme for 
the growth of Mycobacterium tuberculosis was chosen for our study 
after review of literature.  
 A database of 200 molecules with high prospect of inhibiting the target 
1KPI were carefully chosen by making changes to the known hit 
molecules, here the Imidazole nucleus and Benzimidazole nucleus.  
 Candidate molecules were designed and docked against 1KPI protein 
using Argus lab 4.0.1 software.  
 Five molecules with good Docking score (lower binding energy) and 
interactions were shortlisted for synthesis. Reaction conditions were 
optimized.  
 The selected molecules were subjected to toxicity prediction 
assessment by OSIRIS software. The results are colour coded as green 
colour which confirms the drug likeness.  
 The molecules were labelled as M1, M2, M3, M7 and M11 synthesized 
with satisfactory yield.  
 Purity of the synthesized compounds was ensured by repeated 
recrystallization. Further the compounds were evaluated by TLC and 
Melting point determination.  
 The characterization of the synthesized compounds was done using 
Infra-red, Nuclear Magnetic Resonance (H1 NMR) and Mass 
spectroscopic methods (LC-MS, GC-MS).  
 The final pure compounds were screened for Anti- mycobacterial 
activity by in vitro method called Microplate Alamar Blue Assay 
(MABA). 
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CONCLUSION 
 My work concludes that my synthesized molecules are slightly 
effective in inhibiting enzyme Cyclopropane Mycolic acid Synthase-2 
(1KPI), which is important for the growth of Mycobacterium 
tuberculosis Cell wall.  
 Among the four other enzymes the cyclopropane mycolic acid synthase 
2 was the best enzyme for inhibiting Mycobacterium tuberculosis.  
 Streptomycin gave Docking score of -7.4 for 1KPI and Ciprofloxacin 
gave Docking score of -5.9 for 1KPI. There is correlation between the 
score and activities of all the 5 compounds which were tested and 
compared with the standard drugs. This goes to prove that 1KPI is a 
critical enzyme for anti-mycobacterial activity.  
 The Minimum inhibitory concentration of the 5 synthesized compounds 
against H37RV ranged from 50 µg/ml to >100 µg/ml which is 
compared to that of the certain known Anti-TB agents Pyrazinamide- 
3.125μg/ml, Ciprofloxacin- 3.125μg/ml and Streptomycin- 6.25μg/ml.  
 Further structural refinement to the structure of the synthesized 
compounds is expected to yield promising molecules against the 
pathogen Mycobacterium tuberculosis.  
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